PostprintThis is the accepted version of a paper published in Journal of Molecular Biology. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.
Citation for the original published paper (version of record):Covarrubias, A., Högbom, M., Bergfors, T., Carroll, P., Mannerstedt, K. et al. (2008) Structural, biochemical and in vivo investigations of the threonine synthase from Mycobacterium tuberculosis.
Journal of Molecular
* Manuscript
2
SummaryThreonine biosynthesis is a general feature of prokaryotes, eukaryotic microorganisms and higher plants. Since mammals lack the appropriate synthetic machinery, instead obtaining the amino acid through their diet, the pathway is a potential focus for the development of novel antibiotics, anti-fungal agents and herbicides. Threonine synthase, a pyridoxal 5-phosphate-dependent enzyme, catalyses the final step in the pathway, in which L-homoserine phosphate and water are converted into threonine and inorganic phosphate. In the present publication we report structural and functional studies of Mycobacterium tuberculosis threonine synthase, the product of the rv1295 (thrC) gene. The structure gives new insights into the catalytic mechanism of threonine synthases in general, specifically by suggesting the direct involvement of the phosphate moiety of the cofactor, rather than the inorganic phosphate product, in transferring a proton from C4' to C in the formation of the -unsaturated aldimine. It further provides a basis for understanding why this enzyme has a higher pH optimum than has been reported elsewhere for threonine synthases, and gives rise to the prediction that the equivalent enzyme from Thermus thermophilus will exhibit similar behavior. A deletion of the relevant gene generated a strain of M. tuberculosis that requires threonine for growth; such auxotrophic strains are frequently attenuated in vivo, indicating that threonine synthase is a potential drug target in this organism.